For providers
How it compares

An industry standard for breast cancer testing

The Oncotype DX Breast Recurrence Score® test delivers critical genomic information unlike any other genomic test, offering personalized insights to help guide treatment decisions.1-4
A technician's hand working with a lab sample.

Included in major international breast cancer treatment guidelines

The 21-gene assay (Oncotype DX®) is included in leading international oncology guidelines, including those from the National Comprehensive Cancer Network® (NCCN®), the American Society of Clinical Oncology, and the European Society for Medical Oncology (ESMO).5-11*

*National Comprehensive Cancer Network and NCCN are registered trademarks of the National Comprehensive Cancer Network.

  • The only genomic assay with the highest recommendation in 5 major international guidelines for risk assessment in patients with early-stage breast cancer5-9
  • Included as a recommendation in 2 additional guidelines10,11

What sets our test apart

A patient sitting on an exam table talking to her doctor.

It is predictive and prognostic

The Oncotype DX Breast Recurrence Score test is the only test that offers both prognostic and predictive results you can count on for your patients with early-stage invasive breast cancer.3-5,12,13

It is comprehensive

The Oncotype DX Breast Recurrence Score test goes beyond clinicopathological factors, using genomic insights to provide personalized information about the estimated risk of distant recurrence and potential benefit of adjuvant chemotherapy for each unique patient.14-17

Backed by a solid body of clinical evidence

The Oncotype DX Breast Recurrence Score test has been validated across multiple peer-reviewed studies in top-tier journals spanning over 20 years.3,4,12-17
A doctor seated at a desk looking at his laptop.

Ordering a test for your patients is fast and easy

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at 1 866-662-6897.

References

  1. Markopoulos C, Hyams DM, Gomez HL, et al. Multigene assays in early breast cancer: Insights from recent phase 3 studies. Eur J Surg Oncol. 2020;46(4 Pt A):656-666. 
  2. Hyams DM, Schuur E, Aristizabal JA, et al. Selecting postoperative adjuvant systemic therapy for early stage breast cancer: a critical assessment of commercially available gene expression assays. J Surg Oncol. 2017;115(6):647-662. 
  3. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
  4. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
  5. Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Breast Cancer V.4.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 28, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  6. Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816-1837.
  7. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220.
  8. AGO Breast Committee. Diagnosis and Treatment of Patients With Early and Advanced Breast Cancer. Version 2024. 1E. Accessed March 31, 2025. https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2024/englisch/Einzeldateien/AGO_2024E_26_Therapy_algorithms.pdf
  9. Hortobagyi GN, Connolly JL, D'Orsi CJ, et al. Breast. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:589-636.
  10. National Institute for Health and Care Excellence (NICE) Guidelines. Tumor profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Published May 9, 2024. Accessed March 31, 2025. https://www.nice.org.uk/guidance/dg58
  11. Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-1557.
  12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
  13. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829-1834.
  14. Sparano JA, Gray RJ, Mackower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.
  15. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336-2347.
  16. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395-2405.
  17. Sparano JA, Crager M, Gray RJ, et al. Clinical and genomic risk for late breast cancer recurrence and survival. NEJM Evid. 2024;3(8):EVIDoa2300267.

Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, and Recurrence Score are registered trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.

The Oncotype DX Breast Recurrence Score test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority.